Insulin Aspart Injection

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use INSULIN ASPART safely and effectively. See full prescribing information for INSULIN ASPART.

INSULIN ASPART injection, for subcutaneous or intravenous use

Initial U.S. Approval: 2000
This product is NovoLog® (insulin aspart).

— INDICATIONS AND USAGE ——
Insulin Aspart is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus (1).

— DOSAGE AND ADMINISTRATION ——

• See Full Prescribing Information for important preparation, administration, and dosage instructions (2.1, 2.2, 2.3, 2.4, 2.5).

• Subcutaneous injection (2.2):
  - Inject subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
  - Rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis.
  - Should generally be used in regimens with an intermediate- or long-acting insulin.

• Continuous Subcutaneous Insusion (Insulin Pump) (2.2):
  - Refer to the insulin infusion pump user manual to see if NovoLog® (insulin aspart) can be used. Use in accordance with the insulin pump instructions for use.
  - Administer by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer.
  - Rotate the injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
  - Do not mix with other insulins or diluents in the pump.

• Intravenous Administration (2.2):
  - Dilute Insulin Aspart to concentrations from 0.05 unit/mL to 1 unit/mL insulin aspart in infusion systems using polypropylene infusion bags.
  - Insulin Aspart is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP.

— DOSAGE FORMS AND STRENGTHS ——

• Injection: 100 units/mL (U-100) of insulin aspart available as:
  - 10 mL multiple-dose vial (3)
  - 3 mL single-patient-use PenFill® prefilled cartridge for the 3 mL PenFill cartridge device (3)
  - 3 mL single-patient-use FlexPen® prefilled pen (3)

— CONTRAINDICATIONS ——

• During episodes of hypoglycemia (4).
• Hypersensitivity to Insulin Aspart or one of its excipients.

— WARNINGS AND PRECAUTIONS ——

• Never share an Insulin Aspart FlexPen®, PenFill® cartridge or PenFill cartridge device between patients, even if the needle is changed (5.1).

• Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring (5.2).

• Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity, and in patients with renal or hepatic impairments and hypoglycemia unawareness (5.3).

• Medication Errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection (5.4).

• Hypersensitivity reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur. Discontinue Insulin Aspart, treat, and monitor, if indicated (5.5).

• Hypokalemia: May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated (5.6).

• Fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs (5.7).

• Hyperglycemia and Ketonacidosis Due to Insulin Pump Device Malfunction: Monitor glucose and administer Insulin Aspart by subcutaneous injection if pump malfunction occurs (5.8).

— ADVERSE REACTIONS ——

Adverse reactions observed with Insulin Aspart include: hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus (6).

— DRUG INTERACTIONS ——

• Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, diisopyramide, fribates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics (7).

• Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol), epinephrine, terbutaline), and thyroid hormones (7).

• Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine (7).

• Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine (7).

— USE IN SPECIFIC POPULATIONS ——

Pediatric: Has not been studied in children with type 2 diabetes. Has not been studied in children with type 1 diabetes <2 years of age (8.4).

See 17 for PATIENT COUNSELING INFORMATION and FDA approved patient labeling.

Revised: 02/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
  2.1 Important Preparation and Administration Instructions
  2.2 Preparation and Administration Instructions for the Approved Routes of Administration
  2.3 Dosage Recommendations
  2.4 Dosage Modifications for Drug Interactions
  2.5 Instructions for Mixing Insulin Aspart with Other Insulins
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
  5.1 Never Share a Insulin Aspart FlexPen®, PenFill® Cartridge, or PenFill® Cartridge Device between Patients
  5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen
  5.3 Hypoglycemia
  5.4 Hypoglycemia Due to Medication Errors
  5.5 Hypersensitivity Reactions
  5.6 Hypokalemia
  5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists
  5.8 Hyperglycemia and Ketonacidosis Due to Insulin Pump Device Malfunction
6 ADVERSE REACTIONS
  6.1 Clinical Trial Experience
  6.2 Immunogenicity
  6.3 Post Marketing Experience
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.2 Lactation
  8.4 Pediatric Use
  8.5 Geriatric Use
  8.6 Renal Impairment
  8.7 Hepatic Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
  13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
  14.1 Overview of Clinical Studies
  14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes with Subcutaneous Injections
  14.3 Clinical Studies in Adults with Type 2 Diabetes with Subcutaneous Injections
  14.4 Clinical Studies in Adults and Pediatrics with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSI) by External Pump
  14.5 Clinical Studies in Adults with Type 2 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSI) by External Pump
16 HOW SUPPLIED/STORAGE AND HANDLING
  16.1 How Supplied
  16.2 Recommended Storage
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
Continuous Subcutaneous Infusion (Insulin Pump)

1. Always check insulin labels before administration. This product is NovoLog® (insulin aspart) [see Warnings and Precautions (5.4)].
2. Inspect Insulin Aspart visually before use. It should appear clear and colorless. Do not use Insulin Aspart if particulate matter or coloration is seen.
3. In patients with visual impairment, use:
   - Insulin Aspart FlexPen® with caution in those who may rely on audible clicks to dial their dose.
   - PenFil® cartridges with caution.

4. Do not mix Insulin Aspart with other insulins when administering using a continuous subcutaneous infusion pump.

5. Preparation and Administration Instructions for the Approved Routes of Administration

Subcutaneous Injection
1. Inject Insulin Aspart subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
2. Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (8.1) and Adverse Reactions (6.10)].
3. Do not mix Insulin Aspart FlexPen® di stroll units in 1-unit increments.
4. Generally use Insulin Aspart (administered by subcutaneous injection) in regimens with an intermediate- or long-acting insulin.
5. May dilute this Insulin Aspart product with Insulin Diluting Medium for NovoLog® for subcutaneous injection. Dilute one part Insulin Aspart to:
   - Nine parts diluent will yield a concentration one-tenth that of Insulin Aspart (equivalent to U-10).
   - One part diluent will yield a concentration one-half that of Insulin Aspart (equivalent to U-50).

Continuous Subcutaneous Insulin Infusion (Insulin Pump)

1. Can use this Insulin Aspart product with the continuous subcutaneous infusion device. Refer to instructions for use from the pump manufacturer. Refer to the insulin pump user manual to see if the NovoLog® can be used. Use Insulin Aspart in accordance with the pump system's instructions for use.
2. Train patients using continuous subcutaneous insulin pump infusion therapy to administer insulin by injection and have alternate insulin therapy available in case of pump failure.
3. Administer Insulin Aspart by continuous subcutaneous infusion in a regimens that recommend from the pump manufacturer. Rotate infusion sites within the same region to the risk of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (8.1) and Adverse Reactions (6.10)].
4. Instruct patients to follow healthcare provider recommendations when setting basal and meal time infusion rate.
5. Change the Insulin Aspart in the reservoir at least every 7 days or change the infusion set, and insulin set insertion site according to labeled specifications.
6. Do not dilute or mix Insulin Aspart when administering by continuous subcutaneous infusion.
7. Do not expose Insulin Aspart in the pump reservoir to temperatures greater than 98.6°F (37°C).

Intravenous Administration

1. Administer Insulin Aspart intravenously only under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia [see Warnings and Precautions (5.3) and 5.4] and How Supplied/Storage and Handling (16.2).
2. Dilute Insulin Aspart to concentrations of 0.05 U/mL to 1 U/mL, insulin aspart in pH-adjusted diluent systems using polyethylene glycol infiltration bags. Insulin Aspart is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP.

2.3 Dosage Recommendations

1. Individualize the dosage of Insulin Aspart based on the route of administration, the patient's metabolic needs, blood glucose monitoring results and glycemic control goal.
2. Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in disease (i.e., infection or during acute illness) [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6, 8.7)].
3. When switching from another insulin to Insulin Aspart, a different dosage of Insulin Aspart may be needed [see Warnings and Precautions (5.2)].
4. During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].

2.4 Dosage Modifications for Drug Interactions

Dosage modification may be needed when Insulin Aspart is used concomitantly with certain other insulin products [see Drug Interactions (7)].

2.5 Instructions for Mixing Insulin Aspart with Other Insulins

The table below includes instructions regarding mixing Insulin Aspart with other insulins.

Subcutaneous injection route

- Insulin Aspart may only be mixed with NPH insulin preparations.
- If Insulin Aspart is mixed with NPH insulin, withdrawing Insulin Aspart into the syringe first and inject immediately after mixing.

Continuous subcutaneous infusion route (Insulin Pump)

- Do not mix Insulin Aspart with any other insulin.

3. DOSAGE AND STRENGTHS

Injection. 100 units/mL (U-100) is a colorless and colorless solution available as:

- 10 mL multiple-dose vial
- 3 mL single-patient-use PenFil® prefilled cartridges for the 5 mL PenFil® cartridge delivery device with NovoFine® disposable needles
- 3 mL single-patient-use FlexPen® prefilled pen

4. CONTRAINDICATIONS

Insulin Aspart is contraindicated:

- During episodes of hypoglycemia [see Warnings and Precautions (5.3)]
- In patients with hypersensitivity to Insulin Aspart or one of its excipients [see Warnings and Precautions (5.5)]

5. WARNINGS AND PRECAUTIONS

5.1 Never Share a Insulin Aspart FlexPen®, PenFil®, or Cartridge Device between Patients

- Insulin Aspart FlexPen®, PenFil®, and Cartridge devices between Patients Insulin Aspart FlexPen®, PenFil®, and Cartridge devices between Patients [see Warnings and Precautions (5.6)]
- Interim subcutaneous injections with Insulin Aspart may be required. Patients using continuous subcutaneous insulin pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure [see How Supplied/Storage and Handling (16.2) and Patient Counseling Information (17.2)]

6. ADVERSE REACTIONS

The following adverse reactions are also discussed elsewhere:

- Hypoglycemia [see Warnings and Precautions (5.3)]
- Hypoglycemia [see Warnings and Precautions (5.4)]
- Hypoglycemia [see Warnings and Precautions (5.5)]
- Hypoglycemia [see Warnings and Precautions (5.6)]

6.1 Clinical Trial Experience

The adverse event rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice. The safety of Insulin Aspart was evaluated in one two-three trial of 6 months, duration, conducted in patients with diabetes mellitus type 2 diabetes [see Clinical Studies (7.4)]. The data in Table 1 reflect the exposure of 55% patients with type 1 diabetes to Insulin Aspart in one clinical trial with a mean exposure duration to Insulin Aspart of 24 weeks. The mean age was 39 years. Fifty-one percent were male, 94% were Caucasian, 2% were Black and 4% were other races. The mean body mass index (BMI) was 25.6 kg/m². The mean duration of diabetes was 17 years and the mean HbA1c at baseline was 7.9%.

The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to Insulin Aspart in one clinical trial with a mean exposure duration to Insulin Aspart of 24 weeks. The mean age was 57 years. Sixty-three percent were male, 98% were Caucasian, 2% were Black and 1% were other race. The mean BMI was 29.3 kg/m². The mean duration of diabetes was 12.7 years and the mean HbA1c at baseline was 8.1%.

Common adverse reactions were defined as events that occurred in ≥5% of subjects in clinical trials. For adverse events that occurred in the same rate or greater for Insulin Aspart-treated subjects than for placebo, events that occurred at the same rate or greater for Insulin Aspart-treated subjects than for placebo were selected (see Table 1 and 2, respectively). The mean body mass index (BMI) was 25.6 kg/m². The mean duration of diabetes was 17.7 years and the mean HbA1c at baseline was 7.9%.

The data in Table 1 reflect the exposure of 91 patients with type 2 diabetes to Insulin Aspart in one clinical trial with a mean exposure duration to Insulin Aspart of 24 weeks. The mean age was 57 years. Sixty-three percent were male, 98% were Caucasian, 2% were Black and 1% were other race. The mean BMI was 29.3 kg/m². The mean duration of diabetes was 12.7 years and the mean HbA1c at baseline was 8.1%.

The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to Insulin Aspart in one clinical trial with a mean exposure duration to Insulin Aspart of 24 weeks. The mean age was 57 years. Sixty-three percent were male, 98% were Caucasian, 2% were Black and 1% were other race. The mean BMI was 29.3 kg/m². The mean duration of diabetes was 12.7 years and the mean HbA1c at baseline was 8.1%.

The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to Insulin Aspart in one clinical trial with a mean exposure duration to Insulin Aspart of 24 weeks. The mean age was 57 years. Sixty-three percent were male, 98% were Caucasian, 2% were Black and 1% were other race. The mean BMI was 29.3 kg/m². The mean duration of diabetes was 12.7 years and the mean HbA1c at baseline was 8.1%.

Table 1: Adverse reactions that occurred in ≥5% of Type 1 Diabetes Mellitus Adult Patients treated with Insulin Aspart and at the same rate or greater on Insulin Aspart than on comparator

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Type 1 Diabetes Mellitus Insulin Aspart (n=286)</th>
<th>Comparator (n=286)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycemia</td>
<td>5.4%</td>
<td>3.7%</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>5.4%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>11.0%</td>
<td>10.2%</td>
</tr>
<tr>
<td>Headache</td>
<td>12.5%</td>
<td>11.0%</td>
</tr>
<tr>
<td>Injury accidental</td>
<td>11.0%</td>
<td>10.2%</td>
</tr>
<tr>
<td>Nausea</td>
<td>7.5%</td>
<td>5.2%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5.4%</td>
<td>3.7%</td>
</tr>
</tbody>
</table>
Insulin Aspart Injection

<table>
<thead>
<tr>
<th>Insulin Aspart + NPH (%) (n=91)</th>
<th>Human Regular Insulin + NPH (%) (n=91)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperglycemia</td>
<td>11</td>
</tr>
<tr>
<td>Onychomycosis</td>
<td>10</td>
</tr>
<tr>
<td>Sensory disturbance</td>
<td>9</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>8</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5</td>
</tr>
<tr>
<td>Headache</td>
<td>3</td>
</tr>
<tr>
<td>Skin disorder</td>
<td>2</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>1</td>
</tr>
</tbody>
</table>

Severe Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including Insulin Aspart. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for Insulin Aspart with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that will occur in clinical practice.

Severe hypoglycemia was defined as hypoglycemia associated with central nervous system symptoms and requiring the intervention of another person or hospitalization. The incidence of severe hypoglycemia in:

- Adult and pediatric patients with type 1 diabetes mellitus who received subcutaneous Insulin Aspart was 17% at 24 weeks and 6% at 24 weeks, respectively (see Clinical Studies (14)).
- Adult patients with type 2 diabetes mellitus who received subcutaneous Insulin Aspart was 10% at 24 weeks.
- Adult patients with type 2 diabetes mellitus, who received Insulin Aspart via continuous subcutaneous insulin infusion by external pump was 2% at 16 weeks and 10% at 16 weeks respectively.

No severe hypoglycemic episodes were reported in adult patients with type 2 diabetes mellitus receiving Insulin Aspart via continuous subcutaneous insulin infusion by external pump at 16 weeks.

Allergic Reactions

Some patients taking insulin, including Insulin Aspart have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported.

Adverse Reactions Associated with Insulin Initiation and Glucose Control

Intensification

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmic refractive disorder, worsening of dermatologic or ophthalmologic disease, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.

Lipodystrophy

Administration of insulin, including Insulin Aspart, subcutaneously and via subcutaneous insulin infusion, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Weight Gain

Weight gain has occurred with insulins including Insulin Aspart, and has been attributed to the anabolic effects of insulin and the decrease in glucose!

6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Insulin Aspart in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In a 6-month study with a 6-month extension in adult subjects with type 1 diabetes, 99.8% of patients who received Insulin Aspart were positive for anti-insulin antibodies (AIA) at least once during the study, including 97.2% that were positive at baseline. The overall incidence of patients who received Insulin Aspart were positive for anti-drug antibodies (ADA) at least once during the study, including 64.6% that were positive at baseline.

In a phase 3 type 1 diabetes clinical trial of Insulin Aspart, initial increase in titers of antibodies to insulin, followed by a decrease to baseline values, was observed in regular human insulin and insulin aspart treatment groups with similar incidences. These antibodies did not cause deterioration in glycanic control or necessitate increases in dose.

3.5 Use in Specific Populations

8.1 Pregnancy

Risk Summary

Available information from published randomized controlled trials with insulin aspart use during the second trimester of pregnancy have not reported an association with insulin aspart and major birth defects or adverse maternal or fetal outcomes. However, in animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at exposures up to 250 times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents. In rats and rabbits at a dose of 200 units/kg/day (approximately 32 times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents), no significant effects were observed in rats at a dose of 50 units/kg/day and in rabbits at a dose of 3 units/kg/day. These doses are approximately 8 times the human subcutaneous dose of 1 unit/kg/day for rats and equal to the human subcutaneous dose of 1 unit/kg/day for rabbits, based on human exposure equivalents. The effects are considered secondary to maternal toxicity.

8.5 Geriatric Use

Geriatric Use

Prolonged insulin infusion by external pump at 16 weeks.

8.6 Renal Impairment

Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent Insulin Aspart dose adjustment and more frequent blood glucose monitoring (see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)).

8.7 Hepatic Impairment

Patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent Insulin Aspart dose adjustment and more frequent blood glucose monitoring (see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)).

10. OVERDOSAGE

Excess insulin administration may cause hypoglycemia and hypokalemia (see Warnings and Precautions (5.3, 5.7)). Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be necessary. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/ subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

11. DESCRIPTION

Insulin aspart injection is a recombinant human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker’s yeast) with the use of the empirical formula C32H64N6O39S2 and a molecular weight of 5825.8 Da.

Figure 1. Structural formula of insulin aspart.
Insulin injection is a sterile, clear, and colorless solution for subcutaneous or intravenous use. Each mL contains 100 units of insulin Aspart and the inactive ingredients: disodium hydrogen phosphate dihydrate (1.25 mg), glycine (16.0 mg), metacresol (1.72 mg), phenol (1.50 mg), sodium chloride (0.58 mg), zinc (196 mg), and Water for Injection, USP. Insulin Aspart has a pH of 2.2-3.2. Hydrochloric acid 10% and/or sodium hydroxide 10% may be added to adjust pH.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The primary activity of insulin, including Insulin Aspart, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

12.2 Pharmacodynamics

Pharmacodynamics of Insulin Aspart After Subcutaneous Administration

The pharmacodynamic profile of Insulin Aspart given subcutaneously in 22 patients with type 1 diabetes is shown in Figure 2. The maximum glucose-lowering effect of Insulin Aspart occurred between 1 and 3 hours after subcutaneous injection (0.15 units/kg). The duration of action for Insulin Aspart is 3 to 5 hours. The time course of action of insulin and insulin analogs such as Insulin Aspart may vary considerably in different individuals or within the same individual. The parameters of Insulin Aspart activity (time of onset, peak time and duration) as designated in Figure 2 should be considered only as general guidelines. The rate of insulin absorption and onset of activity is affected by the site of injection, exercise, and other variables (seeWarnings and Precautions (2.3)).

Figure 2. Serial mean serum glucose collected up to 6 hours following a single 0.15 units/kg pre-meal dose of insulin Aspart (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 diabetes.

Metabolism and Elimination

In a randomized, double-blind, crossover study 17 healthy Caucasian male subjects between 18 and 40 years of age received an intravenous infusion of either Insulin Aspart or regular human insulin at 1.5 μU/kg/min for 120 minutes. The mean insulin clearance was similar for the two groups with mean values of 1.2 L/h/kg for the Insulin Aspart group and 1.2 L/h/kg for the regular human insulin group.

After subcutaneous administration in normal male volunteers (n=24), Insulin Aspart was eliminated with an average apparent half-life of 81 minutes.

Specific Populations

Pediatric Patients: The pharmacokinetic and pharmacodynamic properties of Insulin Aspart and regular human insulin were evaluated in a single dose study in 18 pediatric patients with type 1 diabetes in 2 age groups: 6-12 years, n=9 and 13-17 years (Tanner grade 2 to 4), n=9. The relative differences in pharmacokinetics and pharmacodynamics in the pediatric patients with type 1 diabetes in both age groups between Insulin Aspart and regular human insulin were similar to those in healthy adult subjects and adults with type 1 diabetes.

Geriatric Patients: The pharmacokinetic and pharmacodynamic properties of Insulin Aspart and regular human insulin were evaluated in a single dose study in 18 subjects with type 2 diabetes who were ≥65 years of age. The relative differences in pharmacokinetics and pharmacodynamics in geriatric patients with type 2 diabetes between Insulin Aspart and regular human insulin were similar to those in younger adults.

Male and Female Patients: In healthy volunteers given a single subcutaneous dose of Insulin Aspart 0.06 units/kg, no difference in insulin aspart levels was seen between males and females based on comparison of AUC (0-10h) and C(max).

Obese Patients: A single subcutaneous dose of 0.1 units/kg Insulin Aspart was administered in a study of 23 patients with type 1 diabetes and a wide range of body mass index (BMI, 22-39 kg/m²). The pharmacokinetic parameters of Insulin Aspart were generally unaffected by BMI in the different groups – BMI <23 kg/m² (n=4); BMI 23-27 kg/m² (n=7); BMI 27-32 kg/m² (n=6) and BMI >32 kg/m² (n=6). Clearance of Insulin Aspart was reduced by 28% in patients with BMI >32 kg/m² compared to patients with BMI <23 kg/m².

Patients with Renal Impairment: A single subcutaneous dose of 0.08 units/kg Insulin Aspart was administered in a study to subjects with either normal renal function (n=6) or mild (n=4) or moderate (n=4) or severe (n=4) renal impairment. In this study, there was no correlation between the degree of hepatic impairment and the Insulin Aspart pharmacokinetic parameter.
The Insulin Aspart FlexPen insulin delivery devices with NovoFine® needles are available as prefilled single-patient-use FlexPen or PenFill® cartridges.

### 14.4 Clinical Studies in Adults and Pediatricts Using Type 2 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSI) by External Pump

**Table 5. Subcutaneous Insulin Aspart Administration in Type 2 Diabetes (6 months; n=116)**

<table>
<thead>
<tr>
<th>Insulin Aspart + NPH (n=90)</th>
<th>Regular Human Insulin + NPH (n=85)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline HbA1c (%)</td>
<td>8.1 ± 0.8</td>
</tr>
<tr>
<td>Change from Baseline HbA1c (%)</td>
<td>-0.3 ± 0.1</td>
</tr>
<tr>
<td>Treatment Difference (HbA1c, Mean) (95% confidence interval)</td>
<td>0.0 (-0.1, 0.0)</td>
</tr>
</tbody>
</table>

*Values are Mean ± SD

**Type 1 Diabetes – Adult (see Table 6)**

A randomized, 16-week, open-label, parallel design study of pediatric patients with type 1 diabetes (n=298) aged 4-18 years compared two subcutaneous infusion regimens administered via an external insulin pump: Insulin Aspart (n=198) or insulin lispro (n=100). These two treatments resulted in comparable changes from baseline in HbA1c (Table 7).

**Table 6. Adult Insulin Pump Study in Type 1 Diabetes (16 weeks; n=118)**

<table>
<thead>
<tr>
<th>Insulin Aspart (n=59)</th>
<th>Buffered human insulin (n=59)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline HbA1c (%)</td>
<td>7.3 ± 0.7</td>
</tr>
<tr>
<td>Change from Baseline HbA1c (%)</td>
<td>0.0 ± 0.5</td>
</tr>
<tr>
<td>Treatment Difference (HbA1c, Mean (95% confidence interval))</td>
<td>0.2 (-0.1, 0.4)</td>
</tr>
</tbody>
</table>

*Values are Mean ± SD

**Type 1 Diabetes – Pediatric (see Table 7)**

A randomized, 16-week, open-label, parallel design study of pediatric patients with type 1 diabetes (n=298) aged 4-18 years compared two subcutaneous infusion regimens administered via an external insulin pump: Insulin Aspart (n=198) or insulin lispro (n=100). These two treatments resulted in comparable changes from baseline in HbA1c (Table 7).

**Table 7. Pediatric Insulin Pump Study in Type 1 Diabetes (16 weeks; n=288)**

<table>
<thead>
<tr>
<th>Insulin Aspart (n=198)</th>
<th>Liriope (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline HbA1c (%)</td>
<td>8.0 ± 0.9</td>
</tr>
<tr>
<td>Change from Baseline HbA1c (%)</td>
<td>-0.1 ± 0.7</td>
</tr>
<tr>
<td>Treatment Difference (HbA1c, Mean (95% confidence interval))</td>
<td>0.1 (-0.3, 0.0)</td>
</tr>
</tbody>
</table>

*Values are Mean ± SD

### 14.5 Clinical Studies in Adults with Type 2 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSI) by External Pump

**Table 8. Pump Therapy in Type 2 Diabetes (16 weeks; n=127)**

<table>
<thead>
<tr>
<th>Insulin Aspart pump (n=66)</th>
<th>Insulin Aspart + NPH (n=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline HbA1c (%)</td>
<td>8.2 ± 1.4</td>
</tr>
<tr>
<td>Change from Baseline HbA1c (%)</td>
<td>-0.6 ± 0.9</td>
</tr>
<tr>
<td>Treatment Difference (HbA1c, Mean (95% confidence interval))</td>
<td>0.1 (-0.3, 0.3)</td>
</tr>
</tbody>
</table>

*Values are Mean ± SD

### 16 How Supplied/Storage and Handling

**16.1 How Supplied**

Insulin Aspart injection 100 units/mL (U-100) is available as a clear and colorless solution in:

- One 10 mL multiple-dose vial per cartridge
- Five 3 mL single-patient-use PenFill® prefilled cartridges per cartridge
- Five 3 mL single-patient-use FlexPen prefilled pens per cartridge

*Insulin Aspart PenFill® cartridges are designed for use with compatible insulin delivery devices with NovoPen® disposable needles. FlexPen® can be used with NovoFine® or NovoTwist® disposable needles. The Insulin Aspart FlexPen® dialed in 1-unit increments.

**16.2 Recommended Storage**

Dispense in the original sealed carton with the enclosed Instructions for Use. Store unused Insulin Aspart in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze Insulin Aspart and do not use Insulin Aspart if it has been frozen. Do not expose Insulin Aspart to excessive heat or light. Do not withdraw Insulin Aspart into a syringe and store for later use. Always remove and discard the needle after each injection from the Insulin Aspart FlexPen and store without a needle attached.

The storage conditions are summarized in the following table:

**Table 9. Storage Conditions for vial, PenFill®, and Insulin Aspart FlexPen®**

<table>
<thead>
<tr>
<th>Insulin Aspart Presentation</th>
<th>Not in-use (unopened)</th>
<th>Not in-use (unopened)</th>
<th>In-use (opened)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room Temperature (up to 30°C [86°F])</td>
<td>Until expiration date</td>
<td>Until expiration date</td>
<td>Room Temperature (up to 30°C [86°F])</td>
</tr>
<tr>
<td>Expiration Temperature (30°C [86°F])</td>
<td>Room Temperature (30°C [86°F])</td>
<td>28 days</td>
<td>28 days (refrigerated/room temperature)</td>
</tr>
<tr>
<td>10 mL multiple dose vial</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>3 mL single patient-use PenFill® cartridges</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>3 mL single patient-use FlexPen®</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
</tbody>
</table>

*For insulin pump use, the total in-use time is 19 days, including 7 days pump in-use time.

**Storage in External Insulin Pump**

Change the Insulin Aspart in the pump reservoir at least every 7 days or in accordance with the pump user manual, whichever is shorter, or after exposure to temperatures that exceed 37°C (98.6°F).

**Storage of Diluted Insulin Aspart**

This Insulin Aspart product diluted with Insulin Diluting Medium for NovoLog® (insulin aspart) to a concentration equivalent to U-10 or equivalent to U-50 prepared as indicated under Dosage and Administration (2.2) may remain in patient use at temperatures up to 30°C (86°F) for 28 days.

**Storage of Insulin Aspart in Intravenous Infusion Fluids**

Infusion bags prepared as indicated under Dosage and Administration (2.2) are stable at room temperature for 24 hours. Some insulin will be initially adsorbed to the material of the infusion.

**17 Patient Counseling Information**

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Never Share an Insulin Aspart FlexPen®, PenFill® Cartridge or FlexPen® Cartridge Device between Patients. Advise patients that they must never share Insulin Aspart FlexPen®, PenFill® cartridge or PenFill® cartridge devices with another person even if the needle is changed, because doing so can carry a risk for transmission of blood-borne pathogens. Advise patients using Insulin Aspart vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens (see Warnings and Precautions (5.1)).

**Hypoglycemia or Hypoglycemia**

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of Insulin Aspart therapy. Inform patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Inform patients on the management of hypoglycemia (see Warnings and Precautions (5.3)).

Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery.

Advise patients that changes in insulin regimen may predispose to hypoglycemia or hyperglycemia that changes in insulin regimen should be made under close medical supervision (see Warnings and Precautions (5.2)).

**Hypersensitivity Reactions**

Advis patients that hypersensitivity reactions have occurred with Insulin Aspart. Inform patients of the symptoms of hypersensitivity reactions (see Warnings and Precautions (5.4)).

Patients Using Continuous Subcutaneous Insulin Pumps

• Train patients in both intensive insulin therapy with multiple injections and in the function of their pump and pump accessories.

This Insulin Aspart product can be used with continuous subcutaneous insulin infusion pumps labeled for use with NovoLOG® (insulin aspart) - refer to the insulin pump user manual to see if NovoLOG® can be used. See recommended infusion sets in the insulin pump user manual.

Instruct patients to replace insulin in the reservoir at least every 7 days or according to the user manual, whichever is shorter, infusion set and infusion set insertion sites should be changed in accordance to the manufacturer’s user manual. By following this schedule, patients avoid insulin degradation, infusion set occlusion, and loss of the insulin preservative.

Instruct patients to discard insulin exposed to temperatures higher than 37°C (98.6°F).

Instruct patients to inform physicians and select a new site for infusion if infusion site becomes erythematous, pruritic, or thickened.

Instruct patients of the risk of rapid hydroglicemia and ketosis due to pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and degraded insulin. If these problems cannot be promptly corrected, instruct patients to resume therapy with subcutaneous insulin injection and contact their physician (see Warnings and Precautions (5) and How Supplied/Storage and Handling (16.2)).

Instruct patients of the risk of hypoglycemia from pump malfunction. If these problems cannot be promptly corrected, instruct patients to resume therapy with subcutaneous insulin injection and contact their physician (see Warnings and Precautions (5) and How Supplied/Storage and Handling (16.2)).

Manufactured by:
Novo Nordisk Inc.
600 Suddards Mill Road
Pinebrook, NJ 07636
U.S. License Number 1261

Distributed by:
Novo Nordisk Pharma, Inc.
Version: 3
NovoLog®, NovoLog®, NovoLog®, NovoLog®, NovoFine®, NovoTwist® are registered trademarks of Novo Nordisk A/S.

1-800-727-8500
© 2023 Novo Nordisk
US23IA00002 3/2023
PATIENT INFORMATION
Insulin Aspart [in-suh-luhm a-sprt] injection, for subcutaneous or intravenous use
This product is NovoLog® (insulin aspart).

Do not share your Insulin Aspart FlexPen®, PenFill® cartridge or PenFill® cartridge compatible insulin delivery device with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

What is Insulin Aspart?
• Insulin Aspart is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Who should not take Insulin Aspart?
Do not take Insulin Aspart if you:
• are having an episode of low blood sugar (hypoglycemia).
• have an allergy to Insulin Aspart or any of the ingredients in Insulin Aspart.

Before taking Insulin Aspart, tell your healthcare provider about all your medical conditions including, if you are:
• pregnant, planning to become pregnant, or are breastfeeding.
• taking new prescription or over-the-counter medicines, vitamins, or herbal supplements.
Before you start taking Insulin Aspart, talk to your healthcare provider about low blood sugar and how to manage it.

How should I take Insulin Aspart?
• Read the Instructions for Use that come with your Insulin Aspart.
• Take Insulin Aspart exactly as your healthcare provider tells you to.
• Insulin Aspart starts acting fast. You should eat a meal within 5 to 10 minutes after you take your dose of Insulin Aspart.
• Know the type and strength of insulin you take. Do not change the type of insulin you take unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you take different types of insulin.
• Check your blood sugar levels. Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels.
• Do not reuse or share your needles with other people. You may give other people a serious infection or get a serious infection from them.
• Insulin Aspart can be injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs (thighs) or upper arms, or by continuous infusion under the skin (subcutaneously) through an insulin pump into an area of your body recommended in the instructions that come with your insulin pump.
• Change (rotate) your injection sites within the area you choose with each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
  • Do not use the exact same spot for each injection.
  • Do not inject where the skin has pits, is thickened, or has lumps.
  • Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.

What should I avoid while taking Insulin Aspart?
While taking Insulin Aspart do not:
• Drive or operate heavy machinery, until you know how Insulin Aspart affects you.
• Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.

What are the possible side effects of Insulin Aspart?
Insulin Aspart may cause serious side effects that can lead to death, including:
Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include:
• dizziness or light-headedness
• sweating
• confusion
• headache
• blurred vision
• slurred speech
• shakiness
• fast heart beat

Your insulin dose may need to change because of:
• change in level of physical activity or exercise
• weight gain or loss
• increased stress
• illness
• change in diet

Other common side effects of Insulin Aspart may include:
• low potassium in your blood (hypokalemia), reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.

Get emergency medical help if you have:
• trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.

These are not all the possible side effects of Insulin Aspart. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of Insulin Aspart.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about Insulin Aspart that is written for health professionals. Do not use Insulin Aspart for a condition for which it was not prescribed. Do not give Insulin Aspart to other people, even if they have the same symptoms that you have. It may harm them.

What are the ingredients in Insulin Aspart?
Active Ingredient: insulin aspart
Inactive Ingredients: disodium hydrogen phosphate dihydrate, glycerin, metacresol, phenol, sodium chloride, zinc, and Water for Injection, USP. Hydrochloric acid 10% and/or sodium hydroxide 10% may be added to adjust pH.
Manufactured by: Novo Nordisk Inc., Plainsboro, NJ 08536, U.S. License Number 1261
For more information, call 1-800-727-6500.

This Patient Information has been approved by the U.S. Food and Drug Administration.
Revised: 02/2023
INSTRUCTIONS FOR USE

Insulin Aspart (in-suh-luhn a-sprt) injection, for subcutaneous or intravenous use
10 mL multiple-dose vial (100 units/mL, U-100)

This product is NovoLog® (insulin aspart).

Read this Instructions for Use before you start taking Insulin Aspart and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Supplies you will need to give your Insulin Aspart injection:
- 10 mL Insulin Aspart vial
- insulin syringe and needle
- alcohol swabs

Preparing your Insulin Aspart dose:
- Wash your hands with soap and water.
- Before you start to prepare your injection, check the Insulin Aspart label to make sure that you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
- Insulin Aspart should look clear and colorless. Do not use Insulin Aspart if it is thick, cloudy, or is colored.
- Do not use Insulin Aspart past the expiration date printed on the label.

Step 1: Pull off the tamper resistant cap (See Figure A).
Step 2: Wipe the rubber stopper with an alcohol swab (See Figure B).

Step 3: Hold the syringe with the needle pointing up. Pull down on the plunger until the black tip reaches the line for your prescribed dose (See Figure C).

Step 4: Push the needle through the rubber stopper of the Insulin Aspart vial (See Figure D).
Step 5: Push the plunger all the way in. This puts air into the Insulin Aspart vial (See Figure E).

Step 6: Turn the Insulin Aspart vial and syringe upside down and slowly pull the plunger down until the black tip is a few units past the line for your dose (See Figure F).

Step 7: Slowly push the plunger up until the black tip reaches the line for your Insulin Aspart dose (See Figure H).

Step 8: Check the syringe to make sure you have the right dose of Insulin Aspart.
Step 9: Pull the syringe out of the vial’s rubber stopper (See Figure I).

Giving your Injection:
- Inject your Insulin Aspart exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you need to pinch the skin before injecting.
- Insulin Aspart can be injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms, infused in an insulin pump (continuous subcutaneous infusion into an area of your body recommended in the instructions that come with your insulin pump), or given through a needle in your arm (intravenously) by your healthcare provider.
- If you inject Insulin Aspart, change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same injection site for each injection. Do not inject where the skin has pits, is thickened, or has lumps. Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
- If you use Insulin Aspart in an insulin pump, you should change your infusion set and injection site according to the manufacturer’s user manual. This Insulin Aspart product can be used with the continuous subcutaneous insulin infusion pumps labeled for use with NovoLog® (insulin aspart) - refer to the insulin pump user manual to see if NovoLog® can be used. Insulin Aspart should be given into an area of your body recommended in the instructions that come with your insulin pump. Change (rotate) your insertion sites within the area you choose for each injection to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the insertion sites. Do not insert into the exact same spot for each insertion. Do not insert where the skin has pits, is thickened, or has lumps. Do not insert where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.

After your injection:
- Do not recap the needle. Recapping the needle can lead to a needle stick injury.
- Put the empty insulin vials, used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes and needles in your household trash.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - leak-resistant, and properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about the safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
How should I store Insulin Aspart?

- **Do not** freeze Insulin Aspart. **Do not** use Insulin Aspart if it has been frozen.
- Keep Insulin Aspart away from heat or light.

**All unopened vials:**
- Store unopened Insulin Aspart vials in the refrigerator at 36°F to 46°F (2°C to 8°C).
- Unopened vials may be used until the expiration date printed on the label, if they have been stored in the refrigerator.
- Unopened vials should be thrown away after 28 days, if they are stored at room temperature.

**After vials have been opened:**
- Opened Insulin Aspart vials can be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature below 86°F (30°C).
- Throw away all opened Insulin Aspart vials after 28 days, even if they still have insulin left in them.
- If using Insulin Aspart in a pump, throw away all opened Insulin Aspart vials after 19 days.

General information about the safe and effective use of Insulin Aspart

- Always use a new syringe and needle for each injection.
- Do not share syringes or needles.
- Keep Insulin Aspart vials, syringes, and needles out of the reach of children.
INSTRUCTIONS FOR USE

Insulin Aspart (in-suhr-ahn-sprit) injection, for subcutaneous or intravenous use
3 mL FlexPen® prefilled pen (100 units/mL, U-100)

This product is NovoLog® (insulin aspart).

Introduction
Please read the following instructions carefully before using your Insulin Aspart FlexPen®.

Do not share your Insulin Aspart FlexPen® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. Insulin Aspart FlexPen® is a disposable, single-patient-use, dial-a-dose insulin pen. You can select doses from 1 to 60 units in increments of 1 unit. Insulin Aspart FlexPen® is designed to be used with NovoFine®, NovoFine® Plus or NovoTwist® needles.

People who are blind or have vision problems should not use this Pen without help from a person trained to use the Pen.

Getting ready
Make sure you have the following items:
• Insulin Aspart FlexPen®
• New NovoFine®, NovoFine® Plus or NovoTwist® needle
• Alcohol swabs

Insulin Aspart Injection FlexPen®

Wash your hands with soap and water. Before you start to prepare your injection, check the label to make sure that you are taking the right type of insulin. This is especially important if you take more than 1 type of insulin. Insulin Aspart should look clear and colorless. Do not use your Insulin Aspart FlexPen® if the liquid contains particles or is colored.

A. Pull off the pen cap (see diagram A).
Wipe the rubber stopper with an alcohol swab.

B. Attaching the needle
Remove the protective tab from a disposable needle. Screw the needle tightly onto your FlexPen®. It is important that the needle is put on straight (see diagram B). Never place a disposable needle on your Insulin Aspart FlexPen® until you are ready to take your injection.

C. Pull off the big outer needle cap (see diagram C).

D. Pull off the inner needle cap and throw it away (dispose of it) (see diagram D).

E. Turn the dose selector to select 2 units (see diagram E).

F. Hold your Insulin Aspart FlexPen® with the needle pointing up. Tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge (see diagram F).

G. Keep the needle pointing upwards, press the push-button all the way in (see diagram G). The dose selector returns to 0.

H. Turn the dose selector to the number of units you need to inject. The pointer should line up with your dose.

I. Insert the needle into your skin. Inject the dose by pressing the push-button all the way in until the 0 lines up with the pointer (see diagram I). Be careful only to push the button when injecting.

J. Keep the needle in the skin for at least 6 seconds, and keep the push-button pressed all the way in until the needle has been pulled out from the skin (see diagram J). This will make sure that the full dose has been given.

K. Do not recap the needle. Recapping can lead to a needle stick injury. Remove the needle from the Insulin Aspart FlexPen® after each injection and dispose of it. This helps to prevent infection, leakage of insulin, and will help to make sure you inject the right dose of insulin.

L. If you do not have a sharps container, carefully slip the needle into the outer needle cap. Safely remove the needle and throw it away as soon as you can.

M. The used Insulin Aspart FlexPen® may be thrown away in your household trash after you have removed the needle.

N. Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.

O. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
• made of a heavy-duty plastic,
• can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
• upright and stable during use,
• leak-resistant, and
• properly labeled to warn of hazardous waste inside the container.

Preparing your Insulin Aspart FlexPen®

Wash your hands with soap and water. Before you start to prepare your injection, check the label to make sure that you are taking the right type of insulin. This is especially important if you take more than 1 type of insulin. Insulin Aspart should look clear and colorless. Do not use your Insulin Aspart FlexPen® if the liquid contains particles or is colored.

A. Pull off the pen cap (see diagram A).
Wipe the rubber stopper with an alcohol swab.

B. Attaching the needle
Remove the protective tab from a disposable needle. Screw the needle tightly onto your FlexPen®. It is important that the needle is put on straight (see diagram B). Never place a disposable needle on your Insulin Aspart FlexPen® until you are ready to take your injection.

C. Pull off the big outer needle cap (see diagram C).

D. Pull off the inner needle cap and throw it away (dispose of it) (see diagram D).

E. Turn the dose selector to select 2 units (see diagram E).

F. Hold your Insulin Aspart FlexPen® with the needle pointing up. Tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge (see diagram F).

G. Keep the needle pointing upwards, press the push-button all the way in (see diagram G). The dose selector returns to 0.

H. Turn the dose selector to the number of units you need to inject. The pointer should line up with your dose.

I. Insert the needle into your skin. Inject the dose by pressing the push-button all the way in until the 0 lines up with the pointer (see diagram I). Be careful only to push the button when injecting.

J. Keep the needle in the skin for at least 6 seconds, and keep the push-button pressed all the way in until the needle has been pulled out from the skin (see diagram J). This will make sure that the full dose has been given.

K. Do not recap the needle. Recapping can lead to a needle stick injury. Remove the needle from the Insulin Aspart FlexPen® after each injection and dispose of it. This helps to prevent infection, leakage of insulin, and will help to make sure you inject the right dose of insulin.

L. If you do not have a sharps container, carefully slip the needle into the outer needle cap. Safely remove the needle and throw it away as soon as you can.

M. The used Insulin Aspart FlexPen® may be thrown away in your household trash after you have removed the needle.

N. Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.

O. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
• made of a heavy-duty plastic,
• can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
• upright and stable during use,
• leak-resistant, and
• properly labeled to warn of hazardous waste inside the container.

Selecting your dose
Check and make sure that the dose selector is set at 0.

Giving the injection
Do the injection exactly as shown to you by your healthcare provider. Your healthcare provider should tell you if you need to pinch the skin before injecting. Wipe the skin with an alcohol swab and let the area dry.

Insulin Aspart can be injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs (thighs), or upper arms. Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipoatrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same injection site for each injection. Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.

I. Insert the needle into your skin. Inject the dose by pressing the push-button all the way in until the 0 lines up with the pointer (see diagram I). Be careful only to push the button when injecting.

J. Keep the needle in the skin for at least 6 seconds, and keep the push-button pressed all the way in until the needle has been pulled out from the skin (see diagram J). This will make sure that the full dose has been given.

K. Do not recap the needle. Recapping can lead to a needle stick injury. Remove the needle from the Insulin Aspart FlexPen® after each injection and dispose of it. This helps to prevent infection, leakage of insulin, and will help to make sure you inject the right dose of insulin.

L. If you do not have a sharps container, carefully slip the needle into the outer needle cap. Safely remove the needle and throw it away as soon as you can.

M. The used Insulin Aspart FlexPen® may be thrown away in your household trash after you have removed the needle.

N. Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.

O. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
• made of a heavy-duty plastic,
• can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
• upright and stable during use,
• leak-resistant, and
• properly labeled to warn of hazardous waste inside the container.

After the injection
Do not recap the needle. Recapping can lead to a needle stick injury. Remove the needle from the Insulin Aspart FlexPen® after each injection and dispose of it. This helps to prevent infection, leakage of insulin, and will help to make sure you inject the right dose of insulin.

I. If you do not have a sharps container, carefully slip the needle into the outer needle cap. Safely remove the needle and throw it away as soon as you can.

M. The used Insulin Aspart FlexPen® may be thrown away in your household trash after you have removed the needle.

N. Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.

O. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
• made of a heavy-duty plastic,
• can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
• upright and stable during use,
• leak-resistant, and
• properly labeled to warn of hazardous waste inside the container.
• When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about the safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal. Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

• When there is not enough medicine left in your Insulin Aspart FlexPen® for your prescribed dose, the Insulin Aspart FlexPen® may be thrown away in your household trash after you have removed the needle.

The Insulin Aspart FlexPen® prevents the cartridge from being completely emptied. It is designed to deliver 300 units.

K. Put the pen cap on the Insulin Aspart FlexPen® and store the Insulin Aspart FlexPen® without the needle attached (see diagram K). Storing without the needle attached helps prevent leaking, blocking of the needle, and air from entering the Pen.

How should I store Insulin Aspart FlexPen®?

• Do not freeze Insulin Aspart. Do not use Insulin Aspart if it has been frozen.

• Keep Insulin Aspart away from heat or light.

• Store the Insulin Aspart FlexPen® without the needle attached.

• Until first use:
  • Store unused Insulin Aspart FlexPen® in the refrigerator at 36°F to 46°F (2°C to 8°C).
  • Unused FlexPen® may be used until the expiration date printed on the label, if kept in the refrigerator.
  • Unused Insulin Aspart FlexPen® stored at room temperature should be thrown away after 28 days.

• In-use:
  • Store the FlexPen® you are currently using out of the refrigerator at room temperature below 86°F (30°C) for up to 28 days.
  • The Insulin Aspart FlexPen® you are using should be thrown away after 28 days, even if it still has insulin left in it.

Maintenance

For the safe and proper use of your FlexPen® be sure to handle it with care. Avoid dropping your FlexPen® as it may damage it. If you are concerned that your FlexPen® is damaged, use a new one. You can clean the outside of your FlexPen® by wiping it with a damp cloth. Do not soak or wash your FlexPen® as it may damage it. Do not refill your FlexPen®.

• Remove the needle from the Insulin Aspart FlexPen® after each injection. This helps to ensure sterility, prevent leakage of insulin, and will help to make sure you inject the right dose of insulin for future injections.

• Be careful when handling used needles to avoid needle sticks and transfer of infectious diseases.

• Keep your Insulin Aspart FlexPen® and needles out of the reach of children.

• Use Insulin Aspart FlexPen® as directed to treat your diabetes.

• Do not share your Insulin Aspart FlexPen® or needles with other people. You may give other people a serious infection, or get a serious infection from them.

• Always use a new needle for each injection.

• Novo Nordisk is not responsible for harm due to using this insulin pen with products not recommended by Novo Nordisk.

• As a precautionary measure, always carry a spare insulin delivery device in case your Insulin Aspart FlexPen® is lost or damaged.

• Remember to keep the disposable Insulin Aspart FlexPen® with you. Do not leave it in a car or other location where it can get too hot or too cold.
INSTRUCTIONS FOR USE

Insulin Aspart PenFill®

Injection, for subcutaneous or intravenous use

PenFill® 3 mL cartridge 100 units/mL (U-100)

This product is NovoLog® (insulin aspart).

• Do not share your PenFill® cartridge or PenFill® cartridge compatible insulin delivery device with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
• Your healthcare provider should show you or your caregiver how to inject Insulin Aspart the right way before you inject it for the first time.
• Insulin Aspart PenFill® cartridge 100 units/mL is a prefilled, single-patient-use cartridge containing 300 units of Insulin Aspart.
• After you insert the PenFill® cartridge in your device, you can use it for multiple injections. Read the instruction manual that comes with your insulin delivery device for complete instructions on how to use the PenFill® cartridge with the device.
• People who are blind or have vision problems should not use this PenFill® cartridge without help from a person trained to use the PenFill® cartridge with the device.
• If using a new Insulin Aspart PenFill® cartridge, start with Step 1.
• If the Insulin Aspart PenFill® cartridge has already been used, start with Step 2.

Supplies you will need to give your Insulin Aspart injection:

• Insulin Aspart PenFill® cartridge
• Novo Nordisk 3 mL PenFill® cartridge compatible insulin delivery device
• 1 new NovoFine®, NovoFine® Plus, or NovoTwist® needle
• Alcohol swabs
• Adhesive bandage
• Cotton gauze
• A sharps container for throwing away used PenFill® cartridges and needles. See “After your injection” at the end of these instructions.

Supplies you will need to give your Insulin Aspart injection:

• NovoFine®
  • Outer needle cap
  • Inner needle cap
  • Needle
  • Paper tab

• NovoFine® Plus
  • Outer needle cap
  • Inner needle cap
  • Needle
  • Paper tab

• NovoTwist®
  • Outer needle cap
  • Inner needle cap
  • Needle
  • Paper tab

• PenFill® cartridge compatible insulin delivery device
  • Pen cap
  • Dose pointer
  • Dose counter
  • Dose selector/dose button

• NovoFine®
  • NovoFine®
  • NovoTwist®

How to use the Insulin Aspart PenFill® cartridge

1. Wash your hands with soap and water.
2. Before you start to prepare your injection, check the Insulin Aspart PenFill® cartridge label to make sure that it contains the insulin you need. This is especially important if you take more than 1 type of insulin.
3. The tamper-resistant foil should be in place before the first use. If the foil has been broken or removed before your first use of the cartridge, do not use it. Call Novo Nordisk at 1-800-727-6500.
4. Carefully look at the cartridge and the insulin inside it. Check that the Insulin Aspart cartridge:
   • is not damaged, for example cracked or leaking
   • is not loose on the threaded end
5. Insulin Aspart should look clear and colorless. Do not use Insulin Aspart if it is cloudy or colored or if the threaded end is loose (See Figure B).

Step 1:

1. Insert a 3 mL cartridge with the threaded end first into your Novo Nordisk 3 mL PenFill® cartridge compatible insulin delivery device (See Figure C).
2. If you drop your device, check the insulin cartridge for damage such as cracks or leaking. If your cartridge is damaged, throw it away and use a new one.

Prepare your device with a new needle

Step 2:

1. Take a new needle, and tear off the paper tab. Always use a new needle for each injection to make sure the needle is free of germs (sterile) and to prevent blocked needles. Do not attach a new needle to your device until you are ready to give your injection. Do not reuse or share your needles with other people. You may give others a serious infection, or get a serious infection from them.
2. Be careful not to bend or damage the needle before you use it.
3. Push the needle straight onto the device. Turn the needle clockwise until it is on tight (See Figure D).

Step 3:

1. Pull off the outer needle cap (See Figure E). Do not throw it away. You will need it after the injection to safely remove the needle.
2. Pull off the inner needle cap and throw it away (See Figure F). Do not try to put the inner needle cap back on the needle.

Step 4:

A drop of insulin may appear at the needle tip. This is normal, but you must still check the insulin flow.

Check the insulin flow

Step 5:

1. Small amounts of air may collect in the cartridge during normal use. You must do an airshot before each injection to avoid injecting air and to make sure you receive the prescribed dose of your medicine.
2. Do the airshot as described in the instruction manual that comes with your device.

Step 7:

1. Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same injection site for each injection. Do not inject where the skin has pits, is thickened, or has lumps. Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
2. Clean your injection site with an alcohol swab. Let your skin dry. Do not touch this area again before injecting.
3. Insert the needle into your skin. Press and hold down the dose button until the dose counter shows “0.” Continue to keep the dose button pressed and keep the needle in your skin and slowly count to 6 (see Figure J).
• Remove the needle from your skin. You may see a drop of insulin Aspart at the needle tip after injecting. This is normal and has no effect on the dose you just received. If blood appears after you take the needle out of your skin, press the injection site tightly with a cotton gauze and cover with an adhesive bandage, if necessary. Do not rub the area.

After your injection

Step 8:
• Lay your outer needle cap on a flat surface. Carefully, lead the needle tip into the outer needle cap without touching the needle (See Figure K) and push the outer needle cap completely on.

• Hold the black cartridge holder on the insulin delivery device and unscrew the needle counterclockwise (See Figure L).
• Throw away (dispose of) the needle in an FDA-cleared sharps container as your healthcare professional has instructed you.
• Put your empty Insulin Aspart PenFill® cartridge and used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and PenFill® cartridges in your household trash.
• If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: • made of heavy-duty plastic, • can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, • upright and stable during use, and • leak-resistant and properly labeled to warn of hazardous waste inside the container.
• When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. Do not reuse or share your needles or syringes with other people. For more information about the safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.
• Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Step 9:
• Keep the 3 mL PenFill® cartridge in the device. Do not store your device with a needle attached. This will prevent infection or leakage of insulin and will make sure that you receive the right dose of Insulin Aspart.
• Put the pen cap on your device after each use to protect the insulin from light (See Figure M).

How should I store my Insulin Aspart PenFill® cartridge?
• Do not freeze Insulin Aspart. Do not use Insulin Aspart if it has been frozen.
• Keep Insulin Aspart away from heat or light.
• Store the Insulin Aspart PenFill® cartridge without the needle attached.

Before use:
• Store unused Insulin Aspart PenFill® cartridges in the refrigerator at 36°F to 46°F (2°C to 8°C).
• Unused PenFill® cartridges may be used until the expiration date printed on the label, if kept in the refrigerator.
• If Insulin Aspart is stored mistakenly outside of refrigeration between 47°F (9°C) to 86°F (30°C) prior to first use, it should be used within 28 days or thrown away.

PenFill® cartridges in use:
• Store the PenFill® cartridge you are currently using in the insulin delivery device at room temperature below 86°F (30°C) for up to 28 days. Do not refrigerate.
• The Insulin Aspart PenFill® cartridge you are using should be thrown away after 28 days, even if it still has insulin left in it.

General Information about the safe and effective use of Insulin Aspart.
• Keep Insulin Aspart PenFill® cartridges and needles out of the reach of children.
• Do not share Insulin Aspart PenFill® cartridges or needles with other people. You may give other people a serious infection, or get a serious infection from them.
• Always carry extra insulin of the same type(s) you use in case of loss or damage.